Third Military Medical University
102
16
17
34
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 102 trials
100.0%
+13.5% vs industry average
22%
22 trials in Phase 3/4
9%
3 of 34 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (102)
High-flow Nasal Cannula Oxygen Therapy Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema
Role: lead
CAR-T Cell Therapy Targeting to CD19 for R/R ALL
Role: collaborator
STOPS Trial: Total vs Subtotal Colectomy for Slow Transit Constipation
Role: lead
Erythrocytapheresis for Chronic Mountain Sickness
Role: lead
Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer
Role: lead
Efficacy and Safety of Lubiprostone in the Treatment of Slow Transit Constipation
Role: lead
Effects of Compound Ejiao Syrup on Exercise Tolerance and Quality of Life in Critically Ill Patients After ICU Discharge: A Double-Blind, Multicenter,Randomized Controlled Clinical Study
Role: lead
Efficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary Aldosteronism
Role: lead
Transcutaneous Auricular Vagus Nerve Stimulation as Adjuvant Treatment for Sepsis Patients
Role: lead
PARLAR-02 Trial：Modified Transanal Drainage Tube Use for Preventing Anastomotic Leakage
Role: lead
Risk of NSAIDs on Anastomotic Leak for Rectal Surgery
Role: lead
Comparison of Electrolyte Beverages and Water as Solvents for Bowel Preparation
Role: lead
Epidural Spinal Cord Stimulation for Lower-limb Impairment in Adrenomyeloneuropathy
Role: lead
Statin Combined with Amlodipine Treats Primary Aldosteronism
Role: lead
Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer
Role: collaborator
Effects of Adrenal Artery Ablation and Spironolactone in Patients With Primary Aldosteronism
Role: lead
Effect of Bariatric Surgery Versus Medical Therapy on Metabolic Syndrome
Role: lead
The Plasma Metabolomics Profiling of Primary Aldosteronism
Role: lead
Effects of SGLT2i on the Cognitive Function in T2DM Patient (ESCDP)
Role: lead
Patient Education in the Clinical Management of Pessary
Role: collaborator